doi:10.48130/ejcc-0026-0013

[1]

Mehrjoei B, Haghnazari L, Bashiri H, Rezvani N. 2024. The diagnostic potential of miR-196a-1 in colorectal cancer. BMC Cancer 24(1):162

doi: 10.1186/s12885-024-11881-y

[2]

Mao Y, Wang W, Yang J, Zhou X, Lu Y, et al. 2024. Drug repurposing screening and mechanism analysis based on human colorectal cancer organoids. Protein & Cell 15(4):285−304

doi: 10.1093/procel/pwad038

[3]

Dahouri A, Sahebihagh MH, Gilani N. 2023. Comparison of sexual function of people with colorectal cancer with and without colostomy bag in Iran: a comparative cross-sectional study. Scientific Reports 13:12558

doi: 10.1038/s41598-023-39728-9

[4]

Hoseini B, Rahmatinejad Z, Goshayeshi L, Bergquist R, Golabpour A, et al. 2022. Colorectal Cancer in North-Eastern Iran: a retrospective, comparative study of early-onset and late-onset cases based on data from the Iranian hereditary colorectal cancer registry. BMC Cancer 22(1):48

doi: 10.1186/s12885-021-09132-5

[5]

Jung G, Hernández-Illán E, Moreira L, Balaguer F, Goel A. 2020. Epigenetics of colorectal cancer: biomarker and therapeutic potential. Nature Reviews Gastroenterology & Hepatology 17(2):111−130

doi: 10.1038/s41575-019-0230-y

[6]

Gupta S. 2022. Screening for colorectal cancer. Hematology/Oncology Clinics of North America 36(3):393−414

doi: 10.1016/j.hoc.2022.02.001

[7]

Li J, Li ZP, Ruan WJ, Wang W. 2024. Colorectal cancer screening: the value of early detection and modern challenges. World Journal of Gastroenterology 30(20):2726−2730

doi: 10.3748/wjg.v30.i20.2726

[8]

Cordero OJ, Mosquera-Ferreiro L, Gomez-Tourino I. 2024. Improving colorectal cancer screening programs. World Journal of Gastroenterology 30(22):2849−2851

doi: 10.3748/wjg.v30.i22.2849

[9]

Shaukat A, Levin TR. 2022. Current and future colorectal cancer screening strategies. Nature Reviews Gastroenterology & Hepatology 19(8):521−531

doi: 10.1038/s41575-022-00612-y

[10]

Bretthauer M. 2011. Colorectal cancer screening. Journal of Internal Medicine 270:87−98

doi: 10.1111/j.1365-2796.2011.02399.x

[11]

Martinou E, Falgari G, Bagwan I, Angelidi AM. 2021. A systematic review on HOX genes as potential biomarkers in colorectal cancer: an emerging role of HOXB9. International Journal of Molecular Sciences 22(24):13429

doi: 10.3390/ijms222413429

[12]

Jia S, Zhang R, Li Z, Li J. 2017. Clinical and biological significance of circulating tumor cells, circulating tumor DNA, and exosomes as biomarkers in colorectal cancer. Oncotarget 8(33):55632−55645

doi: 10.18632/oncotarget.17184

[13]

Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, et al. 2014. Multitarget stool DNA testing for colorectal-cancer screening. New England Journal of Medicine 370(14):1287−1297

doi: 10.1056/nejmoa1311194

[14]

Church TR, Wandell M, Lofton-Day C, Mongin SJ, Burger M, et al. 2014. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 63(2):317−325

doi: 10.1136/gutjnl-2012-304149

[15]

Almeida-Lousada H, Mestre A, Ramalhete S, Price AJ, de Mello RA, et al. 2021. Screening for colorectal cancer leading into a new decade: the "roaring '20s" for epigenetic biomarkers? Current Oncology 28(6):4874−4893

doi: 10.3390/curroncol28060411

[16]

Fatemi N, Tierling S, Es HA, Varkiani M, Mojarad EN, et al. 2022. DNA methylation biomarkers in colorectal cancer: clinical applications for precision medicine. International Journal of Cancer 151(12):2068−2081

doi: 10.1002/ijc.34186

[17]

Constâncio V, Nunes SP, Henrique R, Jerónimo C. 2020. DNA methylation-based testing in liquid biopsies as detection and prognostic biomarkers for the four major cancer types. Cells 9(3):624

doi: 10.3390/cells9030624

[18]

Weisenberger DJ, Liang G, Lenz HJ. 2018. DNA methylation aberrancies delineate clinically distinct subsets of colorectal cancer and provide novel targets for epigenetic therapies. Oncogene 37(5):566−577

doi: 10.1038/onc.2017.374

[19]

Gyparaki MT, Basdra EK, Papavassiliou AG. 2013. DNA methylation biomarkers as diagnostic and prognostic tools in colorectal cancer. Journal of Molecular Medicine 91(11):1249−1256

doi: 10.1007/s00109-013-1088-z

[20]

Wang S, Yan S, Zhu S, Zhao Y, Yan J, et al. 2018. FOXF1 induces epithelial-mesenchymal transition in colorectal cancer metastasis by transcriptionally activating SNAI1. Neoplasia 20(10):996−1007

doi: 10.1016/j.neo.2018.08.004

[21]

Lo PK, Lee JS, Chen H, Reisman D, Berger FG, et al. 2013. Cytoplasmic mislocalization of overexpressed FOXF1 is associated with the malignancy and metastasis of colorectal adenocarcinomas. Experimental and Molecular Pathology 94(1):262−269

doi: 10.1016/j.yexmp.2012.10.014

[22]

Ouyang X, Li S, Ding Y, Xin F, Liu M. 2022. Foxf1 gene increases the risk of osteoporosis in rats by inhibiting osteoblast formation and promoting osteoclast differentiation through the upregulation of NF-κB pathway. Journal of Musculoskeletal & Neuronal Interactions 22(2):242−250

[23]

Jin Y, Liang Z, Lou H. 2020. The emerging roles of fox family transcription factors in chromosome replication, organization, and genome stability. Cells 9(1):258

doi: 10.3390/cells9010258

[24]

Zhu KP, Zhang CL, Ma XL. 2017. Antisense lncRNA FOXF1-AS1 promotes migration and invasion of osteosarcoma cells through the FOXF1/MMP-2/-9 pathway. International Journal of Biological Sciences 13(9):1180−1191

doi: 10.7150/ijbs.21722

[25]

Nilsson G, Kannius-Janson M. 2016. Forkhead Box F1 promotes breast cancer cell migration by upregulating lysyl oxidase and suppressing Smad2/3 signaling. BMC Cancer 16(1):142

doi: 10.1186/s12885-016-2196-2

[26]

Wei HJ, Nickoloff JA, Chen WH, Liu HY, Lo WC, et al. 2014. FOXF1 mediates mesenchymal stem cell fusion-induced reprogramming of lung cancer cells. Oncotarget 5(19):9514−9529

doi: 10.18632/oncotarget.2413

[27]

Saito RA, Micke P, Paulsson J, Augsten M, Peña C, et al. 2010. Forkhead box F1 regulates tumor-promoting properties of cancer-associated fibroblasts in lung cancer. Cancer Research 70(7):2644−2654

doi: 10.1158/0008-5472.can-09-3644

[28]

Wang S, Xiao Z, Hong Z, Jiao H, Zhu S, et al. 2018. FOXF1 promotes angiogenesis and accelerates bevacizumab resistance in colorectal cancer by transcriptionally activating VEGFA. Cancer Letters 439:78−90

doi: 10.1016/j.canlet.2018.09.026

[29]

Shen Y, Wang D, Yuan T, Fang H, Zhu C, et al. 2023. Novel DNA methylation biomarkers in stool and blood for early detection of colorectal cancer and precancerous lesions. Clinical Epigenetics 15(1):26

doi: 10.1186/s13148-023-01443-7

[30]

Lim SB, Joe S, Kim HJ, Lee JL, Park IJ, et al. 2023. Deciphering the DNA methylation landscape of colorectal cancer in a Korean cohort. BMB Reports 56(10):569−574

doi: 10.5483/bmbrep.2023-0106

[31]

Hashimoto Y, Zumwalt TJ, Goel A. 2016. DNA methylation patterns as noninvasive biomarkers and targets of epigenetic therapies in colorectal cancer. Epigenomics 8(5):685−703

doi: 10.2217/epi-2015-0013

[32]

Toiyama Y, Okugawa Y, Goel A. 2014. DNA methylation and microRNA biomarkers for noninvasive detection of gastric and colorectal cancer. Biochemical and Biophysical Research Communications 455(1−2):43−57

doi: 10.1016/j.bbrc.2014.08.001

[33]

Yi JM. 2021. DNA methylation change profiling of colorectal disease: screening towards clinical use. Life 11(5):412

doi: 10.3390/life11050412

[34]

Fu B, Yan P, Zhang S, Lu Y, Pan L, et al. 2018. Cell-free circulating methylated SEPT9 for noninvasive diagnosis and monitoring of colorectal cancer. Disease Markers 2018(1):6437104

doi: 10.1155/2018/6437104

[35]

Zhao G, Liu X, Liu Y, Li H, Ma Y, et al. 2020. Aberrant DNA methylation of SEPT9 and SDC2 in stool specimens as an integrated biomarker for colorectal cancer early detection. Frontiers in Genetics 11:643

doi: 10.3389/fgene.2020.00643

[36]

Zhao G, Liu X, Liu Y, Ma Y, Yang J, et al. 2021. Methylated SFRP2 and SDC2 in stool specimens for Colorectal Cancer early detection: a cost-effective strategy for Chinese population. Journal of Cancer 12(9):2665−2672

doi: 10.7150/jca.52478

[37]

Song L, Jia J, Peng X, Xiao W, Li Y. 2017. The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: a meta-analysis. Scientific Reports 7:3032

doi: 10.1038/s41598-017-03321-8

[38]

Ahlquist DA, Zou H, Domanico M, Mahoney DW, Yab TC, et al. 2012. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology 142(2):248−256

doi: 10.1053/j.gastro.2011.10.031

[39]

Koch A, Joosten SC, Feng Z, de Ruijter TC, Draht MX, et al. 2018. Analysis of DNA methylation in cancer: location revisited. Nature Reviews Clinical Oncology 15(7):459−466

doi: 10.1038/s41571-018-0004-4

[40]

Glöckner SC, Dhir M, Yi JM, McGarvey KE, Van Neste L, et al. 2009. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Research 69(11):4691−4699

doi: 10.1158/0008-5472.can-08-0142

[41]

Moradi K, Babaei E, Ali Hosseinpour Feizi M, Safaralizadeh R, Rezvani N. 2021. Quantitative detection of SRY-Box 21 (SOX21) gene promoter methylation as a stool-based noninvasive biomarker for early diagnosis of colorectal cancer by MethyLight method. Indian Journal of Cancer 58(2):217−224

doi: 10.4103/ijc.ijc_37_19

[42]

Zhang H, Song YC, Dang CX. 2013. Detection of hypermethylated spastic paraplegia-20 in stool samples of patients with colorectal cancer. International Journal of Medical Sciences 10(3):230−234

doi: 10.7150/ijms.5278

[43]

Müller HM, Oberwalder M, Fiegl H, Morandell M, Goebel G, et al. 2004. Methylation changes in faecal DNA: a marker for colorectal cancer screening? The Lancet 363(9417):1283−1285

doi: 10.1016/S0140-6736(04)16002-9

[44]

Chen WD, Han ZJ, Skoletsky J, Olson J, Sah J, et al. 2005. Detection in fecal DNA of colon cancer–specific methylation of the nonexpressed vimentin gene. Journal of the National Cancer Institute 97(15):1124−1132

doi: 10.1093/jnci/dji204

[45]

Wang DR, Tang D. 2008. Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World Journal of Gastroenterology 14(4):524

doi: 10.3748/wjg.14.524

[46]

Huang Z, Li L, Wang J. 2007. Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. Digestive Diseases and Sciences 52(9):2287−2291

doi: 10.1007/s10620-007-9755-y

[47]

Oberwalder M, Zitt M, Wöntner C, Fiegl H, Goebel G, et al. 2008. SFRP2 methylation in fecal DNA—a marker for colorectal polyps. International Journal of Colorectal Disease 23(1):15−19

doi: 10.1007/s00384-007-0355-2

[48]

Kim CG, Lee H, Gupta N, Ramachandran S, Kaushik I, et al. 2018. Role of Forkhead Box Class O proteins in cancer progression and metastasis. Seminars in Cancer Biology 50:142−151

doi: 10.1016/j.semcancer.2017.07.007

[49]

Weng W, Okugawa Y, Toden S, Toiyama Y, Kusunoki M, et al. 2016. FOXM1 and FOXQ1 are promising prognostic biomarkers and novel targets of tumor-suppressive miR-342 in human colorectal cancer. Clinical Cancer Research 22(19):4947−4957

doi: 10.1158/1078-0432.ccr-16-0360

[50]

Cui YM, Jiang D, Zhang SH, Wu P, Ye YP, et al. 2014. FOXC2 promotes colorectal cancer proliferation through inhibition of FOXO3a and activation of MAPK and AKT signaling pathways. Cancer Letters 353(1):87−94

doi: 10.1016/j.canlet.2014.07.008

[51]

Xie R, Wang J, Liu X, Wu L, Zhang H, et al. 2017. RUFY3 interaction with FOXK1 promotes invasion and metastasis in colorectal cancer. Scientific Reports 7:3709

doi: 10.1038/s41598-017-04011-1

[52]

Myatt SS, Lam EWF. 2007. The emerging roles of forkhead box (Fox) proteins in cancer. Nature Reviews Cancer 7(11):847−859

doi: 10.1038/nrc2223

[53]

Lo PK, Lee JS, Liang X, Han L, Mori T, et al. 2010. Epigenetic inactivation of the potential tumor suppressor Gene FOXF1 in breast cancer. Cancer Research 70(14):6047−6058

doi: 10.1158/0008-5472.can-10-1576

[54]

Herrera-Merchan A, Cuadros M, Rodriguez MI, Rodriguez S, Torres R, et al. 2020. The value of lncRNAFENDRR and FOXF1 as a prognostic factor for survival of lung adenocarcinoma. Oncotarget 11(13):1172−1185

doi: 10.18632/oncotarget.22154

[55]

Mitchell SM, Ross JP, Drew HR, Ho T, Brown GS, et al. 2014. A panel of genes methylated with high frequency in colorectal cancer. BMC Cancer 14(1):54

doi: 10.1186/1471-2407-14-54

[56]

Ran L, Chen Y, Sher J, Wong EWP, Murphy D, et al. 2018. FOXF1 defines the core-regulatory circuitry in gastrointestinal stromal tumor. Cancer Discovery 8(2):234−251

doi: 10.1158/2159-8290.cd-17-0468

[57]

Zhao ZG, Wang DQ, Hu DF, Li YS, Liu SH. 2016. Decreased FOXF1 promotes hepatocellular carcinoma tumorigenesis, invasion, and stemness and is associated with poor clinical outcome. OncoTargets and Therapy 9:1743−1752

doi: 10.2147/OTT.S95002

[58]

Lo PK, Lee JS, Sukumar S. 2012. The p53–p21WAF1 checkpoint pathway plays a protective role in preventing DNA rereplication induced by abrogation of FOXF1 function. Cellular Signalling 24(1):316−324

doi: 10.1016/j.cellsig.2011.09.017

[59]

Xu L, He H, Shang Y, Qu X, Sun J. 2022. LINC00022 acts as an oncogene in colorectal cancer progression via sponging miR-375-3p to regulate FOXF1 expression. BMC Cancer 22(1):453

doi: 10.1186/s12885-022-09566-5

[60]

Dastafkan Z, Rezvani N, Amini S. 2023. Diagnostic value of FOXF1 gene promoter-methylated DNA in the plasma samples of patients with colorectal cancer. The International Journal of Biological Markers 38(3−4):194−202

doi: 10.1177/03936155231207109